Sana Alajmovic to step down as CEO of Sigrid Therapeutics in early 2026.
Sigrid Therapeutics CEO Sana Alajmovic to Depart
Stockholm, August 12, 2025 – Sigrid Therapeutics AB (Sigrid) announces that CEO Sana Alajmovic will leave her operational role on January 31, 2026, to take on a new position outside of Sigrid’s operations and which does not compete with the company.
Sana’s decision comes during a period of strong growth for Sigrid, following the launch of Glucose Stabiliser, the completion of SHINE – one of the world’s largest clinical studies in prediabetes – and intensified partnership discussions in preparation for international launch.
“Through her visionary leadership and hard work, Sana has laid the foundation for Sigrid’s next growth phase. The Board is grateful for her efforts and wishes her all the best in her next chapter,” says Mattias Ankarberg, Chairman of the Board at Sigrid.
Sigrid Therapeutics was founded in 2014 based on Professor Tore Bengtsson’s research in metabolic health. Tore, currently Chief Scientific Officer and board member, remains in his roles and continues to lead research and product development.
“Leading Sigrid from a research idea to a company with patented technology, clinical evidence, and commercial products has been an amazing journey. I am incredibly proud of the dedicated team that drives Sigrid forward,” says Sana Alajmovic.
The Board of Directors is now initiating the process to recruit a new CEO.
Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.
